Repare Therapeutics Inc., a clinical-stage precision oncology company, has received an approximately $1.5 million research service payment from Ono Pharmaceutical Company, Ltd. for the achievement of a specified research trigger, under the companies’ 2019 strategic partnership. Under the agreement, Repare is primarily responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan.    “This reflects an impor...